Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations a...

詳細記述

保存先:
書誌詳細
出版年:Pharmaceuticals (Basel)
主要な著者: Hochmair, Maximilian J., Fabikan, Hannah, Illini, Oliver, Weinlinger, Christoph, Setinek, Ulrike, Krenbek, Dagmar, Prosch, Helmut, Rauter, Markus, Schumacher, Michael, Wöll, Ewald, Wass, Romana, Brehm, Elmar, Absenger, Gudrun, Bundalo, Tatjana, Errhalt, Peter, Urban, Matthias, Valipour, Arschang
フォーマット: Artigo
言語:Inglês
出版事項: MDPI 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://ncbi.nlm.nih.gov/pubmed/33171712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110371
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料